BCL2 overexpression in diffuse large B-cell lymphoma.

Translocation (14;18)(q32;q21), which is detected in 20-30% of diffuse large B-cell lymphomas (DLBCL), is regarded as a major mechanism for BCL2 protein overexpression. Nevertheless, BCL2 overexpression is not always caused by t(14;18), because it is often detected in lymphomas without BCL2 rearrangement. Recent studies have shown that increased expression of BCL2 may also result from BCL2 gene amplification in DLBCL. Similarly, it has been speculated that the mutations of the open reading frame might cause increased expression of BCL2 by affecting the interactions of BCL2 with other proteins. The results obtained from studies on the association of BCL2 protein overexpression with survival of DLBCL are controversial, although a correlation with decreased overall survival seems to exist. However, BCL2 rearrangement does not seem to have any major association with poor prognosis, but it is difficult to assess its true impact on prognosis due to differences in treatment and follow-up, and methodologies applied to study the BCL2 rearrangement. This review summarizes the BCL2 expression studies in DLBCL and discusses the prognostic relevance of BCL2 overexpression and its mechanisms.

[1]  R. Chaganti,et al.  Gene amplification in non‐Hodgkin's lymphoma , 1994, British journal of haematology.

[2]  T. Yoshino,et al.  Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. , 1992, Blood.

[3]  K. Franssila,et al.  Major and minor breakpoint sites of chromosomal translocation t(14;18) in subtypes of non-Hodgkin's lymphomas. , 1994, Leukemia research.

[4]  G. Ott,et al.  High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. , 1997, The American journal of pathology.

[5]  R. Warnke,et al.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. , 1987, The New England journal of medicine.

[6]  K. Offit,et al.  18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance , 1989, British journal of haematology.

[7]  C. Bloomfield,et al.  Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. , 1988, Annals of internal medicine.

[8]  J. Diebold,et al.  UPDATED KIEL CLASSIFICATION FOR LYMPHOMAS , 1988, The Lancet.

[9]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[10]  M. Piris,et al.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.

[11]  N. Harris,et al.  bcl‐2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features , 1993, Cancer.

[12]  W. Velasquez,et al.  The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. , 1987, Blood.

[13]  A. Tannapfel,et al.  Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. , 1996, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[14]  S. Korsmeyer,et al.  Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. , 1987, The Journal of clinical investigation.

[15]  L. Looijenga,et al.  Lymphomas with testicular localisation show a consistent BCL-2 expression without a translocation (14;18): a molecular and immunohistochemical study. , 1995, British Journal of Cancer.

[16]  S. Pittaluga,et al.  Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization , 1997, Leukemia.

[17]  R. Warnke,et al.  Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. , 1988, The New England journal of medicine.

[18]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[19]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[20]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[21]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[22]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[23]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[24]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[25]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[26]  K. Franssila,et al.  DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. , 1996, Blood.

[27]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[28]  M. Ladanyi,et al.  Cytogenetic analysis of 434 consecutively ascertained specimens of non‐Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment , 1991, Genes, chromosomes & cancer.

[29]  R. Warnke,et al.  Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. , 1996, Blood.

[30]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[31]  F. Cabanillas,et al.  The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[33]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[34]  K. Offit,et al.  Identification of genetic lesions associated with diffuse large-cell lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Korsmeyer,et al.  Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma. , 1988, The EMBO journal.

[36]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[37]  L. Larsson,et al.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.

[38]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[39]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[40]  John Calvin Reed,et al.  Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. , 1993, Leukemia & lymphoma.

[41]  John Calvin Reed,et al.  Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. , 1992, Blood.

[42]  R. Lukes,et al.  Immunologic characterization of human malignant lymphomas , 1974, Cancer.

[43]  M. Taniwaki,et al.  Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. , 1995, Blood.

[44]  J. Sklar,et al.  Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas , 1986, The Journal of experimental medicine.

[45]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[47]  R. Gascoyne,et al.  Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[48]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[49]  S. Poppema,et al.  Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Cigudosa,et al.  Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.

[51]  John Calvin Reed,et al.  Absence of t(14;18) major and minor breakpoints and of Bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease. , 1991, The American journal of pathology.

[52]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[53]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[54]  Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. , 1991 .

[55]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[56]  D. Sheer.  Catalog of chromosome aberrations in cancer (5th edn): by Felix Mitelman (Bertil Johansson and Fredrik Mertens associated eds) Wiley-Liss, 1994. £345.00 $518.00 (xxi + 4252 pages; 2 volumes) ISBN 0 471 11183 X , 1995 .